menu
    • menu
    [{"orgOrder":0,"company":"Locate Bio","sponsor":"Mercia Ventures","pharmaFlowCategory":"D","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"UNITED KINGDOM","productType":"Large molecule","year":"2024","type":"Funding","leadProduct":"rhBMP-2","moa":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Preclinical","graph3":"Locate Bio","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Orthopedics","amount2New":0.01,"dosageForm":"","sponsorNew":"Locate Bio \/ Mercia Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Locate Bio \/ Mercia Ventures"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Osaka University","pharmaFlowCategory":"D","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"JAPAN","productType":"Cell and Gene therapy","year":"2024","type":"Collaboration","leadProduct":"Pluripotent Stem Cell-derived Therapy","moa":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Preclinical","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"","sponsorNew":"Astellas Pharma \/ Osaka University","highestDevelopmentStatusID":"4","companyTruncated":"Astellas Pharma \/ Osaka University"},{"orgOrder":0,"company":"Redwire Corporation","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Partnership","leadProduct":"ELP-004","moa":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Preclinical","graph3":"Redwire Corporation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"","sponsorNew":"Redwire Corporation \/ Bristol Myers Squibb","highestDevelopmentStatusID":"4","companyTruncated":"Redwire Corporation \/ Bristol Myers Squibb"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Redwire Corporation

                            Country arrow
                            PharmaVenue
                            Not Confirmed

                            Redwire Corporation

                            Country arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ELP-004

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Study Phase : Preclinical

                            Sponsor : Bristol Myers Squibb

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Redwire And Bristol Myers Study Bone Disease Treatments in Space

                            Details : The partnership aims to study model small molecule compounds, including ELP-004, using Redwire’s pharmaceutical drug development platform (PIL-BOX).

                            Brand Name : ELP-004

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 23, 2024

                            Lead Product(s) : ELP-004

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Highest Development Status : Preclinical

                            Sponsor : Bristol Myers Squibb

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Astellas Pharma

                            Japan arrow
                            PharmaVenue
                            Not Confirmed

                            Astellas Pharma

                            Japan arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pluripotent Stem Cell-derived Therapy

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Study Phase : Preclinical

                            Sponsor : Osaka University

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Astellas And Osaka University Partner on Pluripotent Stem Cell Therapy

                            Details : The collaboration aims to develop innovative pluripotent stem cell-derived cartilage organoid cell therapy for the treatment of intervertebral disc degenerative disease.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            July 22, 2024

                            Lead Product(s) : Pluripotent Stem Cell-derived Therapy

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Highest Development Status : Preclinical

                            Sponsor : Osaka University

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Locate Bio

                            United Kingdom arrow
                            PharmaVenue
                            Not Confirmed

                            Locate Bio

                            United Kingdom arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : rhBMP-2

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Study Phase : Preclinical

                            Sponsor : Mercia Ventures

                            Deal Size : $9.8 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Locate Bio Raises £9.2 Million for LDGraft Clinical Study

                            Details : LDGraft (rhBMP-2) by Locate Bio is undergoing early clinical trials for treating degenerative disc disease.

                            Brand Name : LDGraft

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            April 29, 2024

                            Lead Product(s) : rhBMP-2

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Highest Development Status : Preclinical

                            Sponsor : Mercia Ventures

                            Deal Size : $9.8 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth